Ar 6 Rhagfyr 2022, cymeradwyodd yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA) y brechlyn COVID-19 Pfizer-BioNTech ar gyfer plant rhwng chwe mis a phedair blwydd oed. Mae’r JCVI wedi cwrdd i adolygu data diweddar sy’n gysylltiedig â threialon brechlynnau pediatrig Covid-19; gwyliadwriaeth diogelwch brechlynnau pediatrig Covid-19 yn yr Unol Daleithiau, ac epidemioleg Covid-19 yn y DU mewn plant rhwng chwe mis a phedair blwydd oed.
On 6 December 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the Pfizer BioNTech COVID-19 vaccine for children aged six months to four years. The JCVI has met to review recent data related to Covid-19 paediatric vaccine trials, safety surveillance of paediatric Covid-19 vaccines in the United States, and the epidemiology of Covid-19 in the UK in children aged six months to four years.